OncoMatch/Clinical Trials/NCT07286149
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
Is NCT07286149 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments for lung neoplasm malignant.
Treatment: MK-1084 · Patritumab deruxtecan · Sacituzumab tirumotecan · Cetuximab · Rescue Medications — Researchers want to learn if MK-1084, the study medicine, can treat advanced or metastatic non-squamous NSCLC. MK-1084 is a targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread. The goals of this study are to learn: * About the safety of MK-1084 and if people tolerate it when taken with other treatments * How many people have the cancer respond (get smaller or go away) to the treatments
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Biomarker criteria
Required: KRAS g12c mutation
Disease stage
Metastatic disease required
advanced or metastatic non-squamous non-small cell lung cancer (NSCLC)
Prior therapy
Must have received: anti-PD-1 therapy
documented disease progression after receiving 1-2 prior lines of programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) therapy
Must have received: anti-PD-L1 therapy
documented disease progression after receiving 1-2 prior lines of programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) therapy
Must have received: platinum-based chemotherapy
documented disease progression after receiving 1-2 prior lines of ... platinum-based chemotherapy
Cannot have received: KRAS inhibitor
Has received previous treatment with an agent targeting KRAS
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Clermont Oncology Center ( Site 0041) · Clermont, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07286149 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior KRAS inhibitor disqualifies patients from enrollment.
Does this trial require KRAS?
Yes, KRAS g12c mutation is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify